Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Cleveland HeartLab

Request full access

Clinical laboratory and disease management firm, develops biomarker technologies and diagnostic tests

Cleveland, United StatesFounded 2000Biotech & Life Sciences

About Cleveland HeartLab

Cleveland HeartLab operates as a clinical reference laboratory with a specialized focus on the prevention, diagnosis, and management of cardiovascular disease. The firm was established in 2009 as a spin-off from the Cleveland Clinic by co-founders Jake Orville and Dr. Marc Penn. Dr. Penn, a cardiologist and researcher, brought deep scientific expertise in cardiovascular diagnostics, while Orville provided extensive experience in the diagnostic and medical technology industries. Their collaboration aimed to commercialize novel biomarker technologies to address gaps in traditional cardiovascular risk assessment.

The company's business is centered on providing advanced biomarker testing services to clinicians, hospitals, and corporate wellness programs. It generates revenue by performing these specialized tests, which go beyond standard cholesterol panels to identify hidden risks for heart disease. The laboratory is both CAP-accredited and CLIA-certified. A key milestone was the acquisition by Quest Diagnostics in December 2017, which integrated Cleveland HeartLab as its national Cardiometabolic Center of Excellence. This strategic move expanded the availability of its specialized tests through Quest's extensive network.

Cleveland HeartLab's core service involves a suite of proprietary diagnostic tests focused on inflammation, genetics, and metabolic markers, which are often overlooked in routine screenings. Its testing portfolio is based on scientific research, with some technologies licensed exclusively, such as a test for Trimethylamine-N-oxide (TMAO), a gut-produced biomarker linked to heart disease risk. The company emphasizes a multi-marker approach, combining several inflammation and biomarker tests to create a more comprehensive risk profile for patients. This allows for personalized interventions aimed at reducing the likelihood of cardiovascular events like heart attacks and strokes. The company also committed to educating healthcare providers and patients on advancements in cardiovascular risk identification through various forums and materials.

Source: Dealroom company data

Cleveland HeartLab in the Cleveland ecosystem

Live from Dealroom

The Cleveland HeartLab office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

7 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A6 investors entered at this stage

  • Glengary Ventures
  • Zapis Capital Group
  • Second Generation LTD
  • HealthCare Ventures
  • Excel Venture Management
  • Mutual Capital Partners

Series B and later1 investor entered at this stage

  • Advantage Capital
Team profiled 12 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 3 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇺🇸 United States100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Cleveland HeartLab on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Cleveland HeartLab on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.